Why the Immunology Biosimilars Market is set to explode? Top Companies : Amgen, Novartis, Allergan, Merck Animal Health and more

The Global Immunology Market is likely to expand in the coming years driven by the high prevalence of immunological disorders, resulting from environmental factors. According to a report published by Fortune Business Insights, titled “IMMUNOLOGY: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2019-2026,” the market was valued at US$ 77,365.4 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 143,833.2 Mn by 2026 and will exhibit a CAGR of 8.1%.

Sample PDF Brochure at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunology-market-100657

Some of the major companies that are present in the Global Immunology Market are;

• AbbVie
• The Janssen Pharmaceutical Companies of Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Amgen
• Pfizer
• Novartis
• Astellas Pharma US
• Bristol-Myers Squibb
• Merck Animal Health
• UCB SA
• Allergan
• Other Prominent Players

The global immunology market is likely to expand in the coming years driven by the high demand for immunology drugs resulting from the high prevalence of immunological disorders. The severity of immunological disorders has created an increasing awareness around the world. Various initiatives and advisory programs have been conducted by the government as well as public organizations. This, in turn, will fuel the demand for immunology drugs. Furthermore, the increased efficiency of immunology drugs has contributed to better patient outcomes, which in turn has led to subsequent growth of the global immunology market.

Recent Product Approvals by Regulatory Agencies to Bode Well for the Overall Market

The spate of recent regulatory approvals for the immunology products is anticipated to contribute to the overall positive growth of the market. For instance, the recent regulatory approval and the subsequent launch of TREMFYA (Guselkumab) by Janssen Global Services, LLC (Johnson & Johnson), is expected to lead to better outcome for the patients. TREMFYA (Guselkumab) was launched for the treatment of moderate to severe plaque psoriasis, a seriously debilitating immunological disorder. TREMFYA is the only biologic approved for the treatment of moderate to severe plaque psoriasis, that selectively blocks the interleukin (IL)-23, leading to a vast improvement in the symptoms of the patient. Apart from being one of the emerging drugs of the immunology market, Fortune Business Insights predicts that Janssen Global Services, LLC (Johnson & Johnson) latest product offering will have a positive impact on the global immunology market in the forthcoming years

AbbVie Gains FDA Approval of SKYRIZI; Product to Witness High Demand in No Time

The global immunology market has gained impetus from the availability of several regulatory approved drugs. The approval of new drugs and the trends of improvements in clinical efficiencies will bode well for the global immunology market. In 2019, AbbVie received approval from the Food and Drug Administration (FDA) for the usage of ‘SKYRIZI’. The drug was aimed at the treatment of moderate to severe plaque psoriasis. This drug was inclined towards the treatment of adults diagnosed with psoriasis and have been recommended for or undergoing therapy. The drug is likely to gain huge popularity among healthcare professionals and its high clinical efficacy will fuel the demand in the coming years.

Besides product launches and drug approvals, Fortune Business Insights assesses several other factors that have made significant growth contributions to the global immunology market. Companies are encouraged by the growing usage approvals by regulatory authorities across the world. Several company mergers and acquisitions have also accounted for growth of the global immunology market. Some of the leading companies that are operating in the global immunology market are AbbVie Inc., Janssen Global Services, LLC (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc, Novartis AG, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and ALLERGAN.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/immunology-market-100657

Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

About Us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

This release was published on openPR.